Navigation Links
Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan

SUNNYVALE, Calif., March 12 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company received the 2008 North American Medical Devices Product of the Year award, from global growth consulting company Frost & Sullivan, for its CyberKnife(R) Robotic Radiosurgery System.

The Frost & Sullivan Award for Product of the Year is presented each year to the company that has demonstrated excellence in new product development and launch within its industry. The recipient company must have shown innovation by launching a broad line of emerging products and technologies.

"We are pleased that Frost & Sullivan has ranked Accuray number one in overall product success for 2008," said Euan S. Thomson, Ph.D., president and CEO of Accuray Incorporated. "Receiving a prestigious award like this, which is based upon extensive research and in-depth interviews, demonstrates our established competitive advantage and outstanding achievements over the past year."

To identify the recipient of this award, Frost & Sullivan's analyst team tracks all new product launches, R&D spending, products in development, and new product features and modifications through interviews with market participants, and extensive secondary and technology research. All new product launches and new products in development in each company are then compared and evaluated based on degree of innovation and customer satisfaction.

"Accuray Incorporated has established itself in the field of robotic radiosurgery with the CyberKnife System and continues to expand its product portfolio through the launch of new products," said Archana Swathy, Frost & Sullivan analyst. "The increased use of the CyberKnife has established a transformation in the treatment regime and has also succeeded in expanding its potential. These collective factors make Accuray's CyberKnife Robotic Radiosurgery System the worthiest recipient of the 2008 Frost & Sullivan Medical Devices Product of the Year Award."

For more information about Frost & Sullivan's Best Practices Awards, visit

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 125 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: procedure growth, market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hospital Corporation of America Purchases Seventh CyberKnife(R) System
2. Cutting Edge CyberKnife Cancer Treatment Center to Open in Tampa Bay Area
3. Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System
4. Leading Russian Cancer Center Acquires CyberKnife(R) System
5. CyberKnife Radiosurgery Expands to India
6. CyberKnife Centers of Miami, Palm Beach and Tampa Invited to Join M.D. Anderson Cancer Center Study
7. St. Louis University Hospital Purchases Second CyberKnife(R) System
8. Independent Survey Names CyberKnife(R) System Most Widely Used Extracranial Radiosurgery Technology
9. Different method of evaluating the urinary tract system reduces radiation dose
10. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
11. Exempla Healthcare Contracts For Talismans Quality Donor System
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... by UPMC and KingMed Diagnostics researchers. Their review of ... that consultation with UPMC pathologists resulted in significantly altered treatment plans for more ...
(Date:11/30/2015)... ... 30, 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz and ... to coincide with World AIDS Day. The multi-media project will be in audio documentary ... as he was dying of the disease. , A collaborative effort led by author, ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... promoting breast and prostate cancer education and prevention—is joining forces with the award-winning ... philanthropy and Hollywood elegance on December 7, 2015 at the Union League of ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage ... effective immediately. , “We are pleased to announce our expanded distribution agreement ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i ... years, announced today that Michigan-based Family Health Center (FHC) has selected i2iTracks as ... years, FHC was awarded the largest Affordable Care Act grant for Federally Qualified ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... YORK , Nov. 30, 2015 Cumberland Pharmaceuticals ... will present live at on December 3, 2015. ... --> TIME: 3:15p.m. ET LINK: ... ET LINK: --> ... online event where investors are invited to ask the company ...
(Date:11/30/2015)... Nov. 30, 2015 Varian Medical Systems (NYSE: VAR ... educational partnership with Apollo Hospitals Group, the largest hospital chain in ... help train radiation technologists in the country. The MoU was signed ... Knowledge, and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its Access ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
Breaking Medicine Technology: